Cell Culture Media Market Size To Reach $12.80 Billion By 2033

August 2025 | Report Format: Electronic (PDF)

Cell Culture Media Market Growth & Trends

The global cell culture media market size is expected to reach USD 12.80 billion by 2033, registering a CAGR of 13.20% from 2025 to 2033, according to a new report by Grand View Research, Inc. Expansion of biosimilars and biologics, growth in stem cell research, and emerging bio manufacturing technologies for cell-based vaccines are the major factors which are likely to drive the market. For instance, in October 2021, the Australian Government funded the Australian-led stem cell research through USD 25 million in grants.

The expansion of clear, regulatory approval paths for biosimilars in emerging markets is generating great opportunities for biosimilar monoclonal antibodies. The availability of an approval pathway in the U.S., has led to new opportunities for bio manufacturers to enter major markets around the globe. Biosimilar versions of monoclonal antibodies have the probability to offer cost reductions of 25-30%, and many emerging market countries are vigorously developing pathways for approvals and are swiftly catching up. As this industry is expanding the key biopharmaceutical players are adopting robust culturing technologies to meet the increasing demand; thereby driving the growth of the market.

Moreover, there is growing interest in improving the stem cell culture, because this technology is being used extensively in research for studying the stem cell biology, as well as for therapeutic applications. Furthermore, funding related to this research field has augmented in recent years which has accelerated the growth of the market. In addition to this, key media manufacturers launched new products for stem cell research. For instance, in September 2021, Bio-Techne Corporation launched a novel medium for the maintenance and expansion of induced pluripotent stem cells having applications in both translational and research workflows.

The outbreak of COVID-19 pandemic has improved the demand for well-established cell-based vaccine production technologies. Moreover, it has given rise to a few scientific innovations, particularly in the production and testing of vaccine technology. For instance, the Vero line originated from the African green monkey kidney and has been extensively used for viral vaccine manufacturing. It has also been used for the development of various SARS-CoV variants. ProVeroTM1 Serum-free Medium is one such medium manufactured by Lonza Bioscience which is protein-free, and of non-animal origin designed to support the growth of Vero cells and MDCK.

Moreover, in many European countries, cell-based flu vaccines have been approved. A probable advantage of cell culture technology is that it authorizes faster start-up of the manufacturing of vaccines during the pandemic. Today, the development of superior biological models, the optimization of culture growth medium, and the reduced dependence on animal-derived components endure to drive the rapidly developing vaccine development.

On the other hand, ethical issues concerning the use of animal-derived products hinders the industry growth. For instance, FBS is collected from the blood of fetal calves is one of the major ethical issues of serum containing media. It is projected that 600,000 liters of FBS is achieved from up to 1.8 million bovine fetuses are produced globally every year, presenting momentous scientific and ethical challenges. To overcome this issue, numerous workshops were held in the past on the replacement of fetal bovine serum and possible ways to reduce the use of FBS in media.

key Request a free sample copy or view report summary: Cell Culture Media Market Report

Cell Culture Media Market Report Highlights

The serum-free media segment held the highest revenue share of 33.16% of the market 2024. The stem cell culture media segment is expected to grow significantly during the forecast period.
The biopharmaceutical production segment dominated the market with a revenue share of 47.79% in 2024. The diagnostics segment is expected to grow at a significant CAGR during the forecast period.
The liquid media segment captured the largest revenue share in 2024. The semi-solid and solid media segment is expected to grow at a significant CAGR during the forecast period.
The pharmaceutical & biotechnology companies segment captured the highest revenue share of 34.17% in 2024. The hospital and diagnostic laboratory segment is projected to grow significantly during the forecast period.
The North America cell culture media market dominated the industry with a share of 38.57% in 2024. The Asia Pacific cell culture media market is expected to grow at the fastest CAGR of 15.16% from 2025 to 2033.

Cell Culture Media Market Segmentation

Grand View Research has segmented global cell culture media market report based on product, application, type, end-use, and region:

Cell Culture Media Product Outlook (Revenue, USD Million, 2021 - 2033)

Serum-free Media
- CHO Media
- BHK Medium
- Vero Medium
- HEK 293 Media
- Other Serum-free media
Classical Media
Stem Cell Culture Media
- Mesenchymal Stem Cells (MSCs)
- Hematopoietic Stem Cells (HSCs)
- Induced Pluripotent Stem Cells (iPSCs)
- Other Stem Cells
Immunology Media
- T Cells
- B Cells
- Natural Killer (NK) Cells
- Other Immune Cells
Specialty Media
Chemically Defined Media
Other Cell Culture Media

Cell Culture Media Application Outlook (Revenue, USD Million, 2021 - 2033)

Biopharmaceutical Production
- Monoclonal Antibodies
- Vaccines Production
- Other Therapeutic Proteins
Diagnostics
Drug Screening and Development
Tissue Engineering and Regenerative Medicine
- Cell and Gene Therapy
- Other Tissue Engineering and Regenerative Medicine Applications
Other Applications